Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Pediatr Infect Dis J ; 27(1): 49-53, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-18162938

RESUMO

BACKGROUND: Multidrug resistance (MDR), specifically to ampicillin and chloramphenicol, has complicated the treatment of Haemophilus influenzae type b (Hib) meningitis. This is worsened by use of prior antibiotics, which limits identification of the causative agent by culture and increases reliance on antigen detection. OBJECTIVE: We aimed to develop a PCR assay for detecting the family of Haemophilus integrating and conjugative elements (ICEs) represented by ICEHin1056 among antibiotic resistant Hib, and then apply this directly to CSF to diagnose Hib meningitis and predict organism susceptibility, irrespective of culture results. STUDY DESIGN: Primers specific for orf 51 of ICEHin1056 were designed and multiplexed with Bex primers, specific for H. influenzae, and tested on culture positive and negative cases. RESULTS: Of 73 Hib isolates, orf 51 PCR amplicons, predicting the presence of ICEs, were found in all 33 MDR isolates while only in 1 of 33 sensitive strains. The remaining 7 ampicillin susceptible, chloramphenicol and tetracycline resistant strains did not produce a PCR product to orf 51. PCR amplification from CSF specimens of these culture positive cases produced identical results with 100% and 97% positive and negative predictive values, respectively. Multiplex PCR to detect Bex and orf 51 identified another 16 MDR Hib cases among 81 culture-negative CSF samples. CONCLUSIONS: Direct PCR for orf 51 in CSF identified resistance pattern of 51% more Hib strains than culture alone (110 versus 73). The ability to detect MDR, in culture negative Hib meningitis cases has significant implications for better directing antibiotic treatment of meningitis cases and thus for preventing disability and death.


Assuntos
Líquido Cefalorraquidiano/microbiologia , Farmacorresistência Bacteriana Múltipla/genética , Haemophilus influenzae tipo b/genética , Meningite por Haemophilus/diagnóstico , Meningite por Haemophilus/tratamento farmacológico , Reação em Cadeia da Polimerase/métodos , Transportadores de Cassetes de Ligação de ATP/genética , Ampicilina/farmacologia , Proteínas de Bactérias/genética , Pré-Escolar , Cloranfenicol/farmacologia , Haemophilus influenzae tipo b/isolamento & purificação , Humanos , Lactente , Sequências Repetitivas Dispersas/genética , Meningite por Haemophilus/microbiologia , Testes de Sensibilidade Microbiana , Valor Preditivo dos Testes , Tetraciclina/farmacologia
2.
Pediatr Res ; 61(5 Pt 1): 588-93, 2007 May.
Artigo em Inglês | MEDLINE | ID: mdl-17413870

RESUMO

Topical emollient therapy may reduce the incidence of serious infections and mortality of preterm infants in developing countries. We tested whether emollient therapy reduced the burden of pathogens on skin and/or prevented bacterial translocation. Neonates <33 wk gestational age were randomized to treatment with sunflower seed oil (SSO) or Aquaphor or the untreated control group. Skin condition score and skin cultures were obtained at enrollment and on d 3, 7, and weekly thereafter, and blood cultures were obtained for episodes of suspected nosocomial sepsis. For analysis, blood cultures were paired with skin cultures obtained 0-3 d before the blood culture. Skin condition scores at 3 d were better in patients treated with either emollient compared with untreated controls; however, skin flora was similar across the groups. The SSO group showed a 72% elevated odds of having a false-positive (FP) skin culture associated with a negative blood culture (i.e. skin flora blocked from entry into blood) compared with the control group. Topical therapy with SSO reduced the passage of pathogens from the skin surface into the bloodstream of preterm infants.


Assuntos
Emolientes/uso terapêutico , Doenças do Prematuro/microbiologia , Doenças do Prematuro/terapia , Recém-Nascido Prematuro , Recém-Nascido de muito Baixo Peso/fisiologia , Óleos de Plantas/uso terapêutico , Pele/microbiologia , Administração Tópica , Bangladesh , Emolientes/administração & dosagem , Feminino , Idade Gestacional , Humanos , Recém-Nascido , Doenças do Prematuro/mortalidade , Controle de Infecções/métodos , Óleos de Plantas/administração & dosagem , Gravidez , Estudos Prospectivos , Óleo de Girassol
3.
Pediatr Infect Dis J ; 25(12): 1137-41, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17133159

RESUMO

BACKGROUND: Quinolone-induced arthropathic toxicity in weight-bearing joints observed in juvenile animals during preclinical testing has largely restricted the routine use of ciprofloxacin in the pediatric age group. As histopathologic, radiologic and magnetic resonance imaging monitoring evidence has gathered supporting the safety of fluoroquinolones in children, many pediatricians have started to prescribe quinolones to some patients on a compassionate basis. OBJECTIVE: The objective of this study was to ascertain the safety of ciprofloxacin in preterm neonates <33 weeks gestational age treated at Dhaka Shishu (Children) Hospital in Bangladesh. METHODS: Long-term follow up was done to monitor the growth and development of preterm infants who were administered intravenous ciprofloxacin in the neonatal period. Ciprofloxacin was used only as a life-saving therapy in cases of sepsis produced by bacterial agents resistant to other antibiotics. Another group of preterm neonates with septicemia who were not exposed to ciprofloxacin, but effectively treated with other antibiotics and followed up, were matched with cases for gender, gestational age and birth weight and included as a comparison group. Forty-eight patients in the ciprofloxacin group and 66 patients in the comparison group were followed up for a mean of 24.7 +/- 18.5 months and 21.6 +/- 18.8 months, respectively. RESULTS: No osteoarticular problems or joint deformities were observed in the ciprofloxacin group during treatment or follow up. No differences in growth and development between the groups were found. CONCLUSIONS: Ciprofloxacin is a safe therapeutic option for newborns with sepsis produced by multiply resistant organisms.


Assuntos
Desenvolvimento Infantil/efeitos dos fármacos , Ciprofloxacina/efeitos adversos , Ciprofloxacina/uso terapêutico , Doenças do Prematuro/tratamento farmacológico , Recém-Nascido Prematuro/crescimento & desenvolvimento , Sepse/tratamento farmacológico , Bangladesh , Feminino , Seguimentos , Humanos , Lactente , Recém-Nascido , Injeções Intravenosas , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA